<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88937">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769352</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00074523</org_study_id>
    <nct_id>NCT01769352</nct_id>
  </id_info>
  <brief_title>Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST)</brief_title>
  <acronym>TEMPEST</acronym>
  <official_title>Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the change in visual acuity of patients with post
      surgical cystoid macular edema who will be treated with two different regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the mean change in BCVA over 12 weeks of Prednisolone Acetate 1% q1h (every hour) WA
      (While Awake)+ Ketorolac 0.5% qid ( four times a day) versus Prednisolone Acetate qid +
      Ketorolac qid for post surgical cystoid macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change from baseline in BCVA</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Post-surgical Cystoid Macular Edema (PSCME)</condition>
  <arm_group>
    <arm_group_label>PredA q1h WA + Kelac qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PredA q1h WA + Kelac qid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PredA qid + Kelac qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PredA qid + Kelac qid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PredA  + Kelac</intervention_name>
    <arm_group_label>PredA q1h WA + Kelac qid</arm_group_label>
    <arm_group_label>PredA qid + Kelac qid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than or equal to 18 years

          -  Diagnosis of PSCME in study eye confirmed by FA showing leakage from retinal vessels
             resulting in pooling of dye in the fovea and Spectralis SD-OCT showing intraretinal
             fluid in or around the fovea.

          -  BCVA score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using
             the ETDRS protocol at a distance of 4 meters).

          -  In the opinion of the investigator, decreased vision in the study eye is due to
             foveal thickening from PSCME and not to any other reason.

        Exclusion Criteria:

          -  Any patient who has other retinal diseases known to cause macular edema (choroidal
             neovascularization, vein occlusion, diabetic macular edema in the study eye).
             Patients with nonexudative Age Related Macular Degeneration (ARMD) or
             non-proliferative diabetic retinopathy without macular edema can be included in the
             study.

          -  Other reason for decreased visual acuity (such as amblyopia, foveal atrophy, optic
             atrophy).

          -  Pre-existing diagnosis of glaucoma in the study eye

          -  Inability to comply with study or follow up procedures

          -  Pregnancy (Women of child bearing age will be asked to take a urine pregnancy test
             prior to enrolling in the study).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulnar Hafiz, MD, MPH</last_name>
    <email>ghafiz1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulnar Hafiz, MD MPH</last_name>
    </contact>
    <investigator>
      <last_name>Peter A Campochiaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia M Krispel, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raafay Sophie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Peter A Campochiaro, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
